#MRNA
-

Moderna Stock Soars 93% After Phase 3 Melanoma Trial Win
Moderna shares nearly doubled after a positive Phase 3 readout for its personalized melanoma therapy with Merck. The rally added…

Moderna shares nearly doubled after a positive Phase 3 readout for its personalized melanoma therapy with Merck. The rally added…